[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
1. Shome D, Bell D, Esmaeli B: Eyelid carcinoma in patients with systemic lymphoma. J Ophthalmic Vis Res; 2010 Jan;5(1):38-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid carcinoma in patients with systemic lymphoma.
  • PURPOSE: To describe a series of patients with Non-Hodgkin's lymphoma (NHL) and concomitant eyelid carcinoma.
  • METHODS: In this non-comparative interventional case series, we retrospectively reviewed the medical records of 5 patients with NHL who developed eyelid carcinoma.
  • Systemic lymphoma had been diagnosed 1 to 72 months prior to development of the eyelid carcinoma.
  • The lesions were basal cell carcinoma in three, and squamous cell carcinoma in two cases.
  • Four patients underwent surgical excision of the carcinoma and one patient was awaiting surgical treatment after completing systemic chemotherapy.
  • Two patients had perineural invasion; one received adjuvant radiotherapy postoperatively but the other did not due to receiving systemic chemotherapy for recurrent NHL.
  • Perineural invasion is frequently encountered in this situation and should be treated with adjuvant radiation therapy to decrease the likelihood of local recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1975 Apr 21;232(3):267-9 [47401.001]
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):223-34 [10882178.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2008 Nov-Dec;24(6):444-9 [19033839.001]
  • [Cites] Am J Ophthalmol. 1986 Apr 15;101(4):480-2 [3515953.001]
  • [Cites] Arch Ophthalmol. 1980 Oct;98(10):1771-2 [7000053.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1847-50 [8956805.001]
  • [Cites] Acta Haematol. 1997;98(1):44-6 [9210914.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):641-5 [10048959.001]
  • [Cites] Dermatology. 2001;202(4):359-61 [11455161.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Curr Treat Options Oncol. 2004 Jun;5(3):215-23 [15115650.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):507-13 [15160912.001]
  • [Cites] Histopathology. 2004 Aug;45(2):162-70 [15279635.001]
  • [Cites] Arch Dermatol. 2004 Aug;140(8):985-8 [15313816.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):49-54 [15621780.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):38-42; discussion 42 [15720094.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1051-5 [16019557.001]
  • [Cites] Skinmed. 2005 Sep-Oct;4(5):300-4 [16282752.001]
  • [Cites] Australas J Dermatol. 2006 Nov;47(4):231-6 [17034463.001]
  • (PMID = 22737325.001).
  • [ISSN] 2008-2010
  • [Journal-full-title] Journal of ophthalmic & vision research
  • [ISO-abbreviation] J Ophthalmic Vis Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3380669
  • [Keywords] NOTNLM ; Eyelid Cancer / Immunosuppression / Squamous Cell Carcinoma / Systemic Lymphoma
  •  go-up   go-down


2. Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I: Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer; 2009;9:262
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.
  • BACKGROUND: Aggressive non-melanoma skin cancer (deeply infiltrating, recurrent, and morphea form lesions) are therapeutically challenging because they require considerable tissue loss and may demand radical disfiguring surgery.
  • The aim of this work was to evaluate the effect of a formulation containing IFNs-alpha and -gamma in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC).
  • METHODS: Patients with extensive, recurrent, resistant to other procedures BCC or SCSC received the IFN formulation peri- and intralesionally, three times per week for 3 weeks.
  • They had been previously treated with surgery and/or radiotherapy or chemotherapy.
  • Thirteen weeks after the end of treatment, the original lesion sites were examined for histological evidence of remaining tumor.
  • At the end of treatment 47% CR (complete tumor elimination), 40% PR (>30% tumor reduction), and 13% stable disease were obtained.
  • None of the patients relapsed during the treatment period.
  • Principal adverse reactions were influenza-like symptoms well known to occur with interferon therapy, which were well tolerated.
  • CONCLUSION: The peri- and intralesional combination of IFNs-alpha and -gamma was safe and showed effect for the treatment of advanced, recurrent and resistant to previous treatments of BCC and SCSC in elder patients.
  • This is the first report of such treatment in patients with advance non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Interferons / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Bayes Theorem. Drug Resistance, Neoplasm. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Prospective Studies. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2726-34 [10537335.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1033-8 [16713458.001]
  • [Cites] Science. 2000 Jun 30;288(5475):2357-60 [10875919.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2001 Jan;239(1):35-40 [11271459.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34 [11900988.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):933-7 [12072058.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jun;22(6):719-28 [12162884.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1485-95 [12368221.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] Acta Ophthalmol Scand. 2002 Dec;80(6):674-5 [12485296.001]
  • [Cites] Dermatol Surg. 2003 Oct;29(10):1027-34 [12974699.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Dermatol Surg. 2004 Jan;30(1):116-20 [14692941.001]
  • [Cites] Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402 [15197337.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):342-6 [2405109.001]
  • [Cites] EMBO J. 1990 Apr;9(4):1105-11 [2108862.001]
  • [Cites] Int Ophthalmol. 1990 Jul;14(4):285-94 [2370130.001]
  • [Cites] Cancer Immunol Immunother. 1990;31(5):321-4 [2115817.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1637-49 [2120392.001]
  • [Cites] J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):694-700 [2229497.001]
  • [Cites] Arch Dermatol. 1990 Dec;126(12):1660 [2256701.001]
  • [Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9 [1869642.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):235-41 [1734084.001]
  • [Cites] J Am Acad Dermatol. 1992 Jul;27(1):65-9 [1619079.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Ann Ophthalmol. 1993 Jan;25(1):11-3 [8427483.001]
  • [Cites] Drug Saf. 1994 Feb;10(2):115-50 [7516663.001]
  • [Cites] J Am Acad Dermatol. 1994 Nov;31(5 Pt 2):916-20 [7962748.001]
  • [Cites] Drugs. 1995 Jul;50(1):48-61 [7588089.001]
  • [Cites] Chin Med Sci J. 2007 Mar;22(1):38-43 [17441316.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1974-8 [17513803.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):889-92 [17638733.001]
  • [Cites] J Immunother. 2008 Jan;31(1):28-33 [18157009.001]
  • [Cites] Acta Pol Pharm. 2008 May-Jun;65(3):345-51 [18646554.001]
  • [Cites] J Immunother. 2008 Sep;31(7):599-606 [18600184.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):205-13 [18849299.001]
  • [Cites] Br J Nurs. 2009 Mar 26-Apr 8;18(6):346, 348-50 [19329898.001]
  • [Cites] Cancer Detect Prev. 1997;21(2):191-5 [9101080.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2691-6 [9389732.001]
  • [Cites] Dermatol Clin. 1998 Apr;16(2):377-98 [9589211.001]
  • [Cites] Acta Oncol. 1999;38(5):613-7 [10427950.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1849-57 [15547726.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 May;131(5):300-4 [15619125.001]
  • [Cites] Ophthalmology. 2005 Apr;112(4):717-23 [15808267.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2937-46 [15837745.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):217-22 [10605014.001]
  • (PMID = 19643007.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9008-11-1 / Interferons
  • [Other-IDs] NLM/ PMC2724551
  •  go-up   go-down


3. Lebwohl M, Tannis C, Carrasco D: Acitretin suppression of squamous cell carcinoma: case report and literature review. J Dermatolog Treat; 2003;14 Suppl 2:3-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acitretin suppression of squamous cell carcinoma: case report and literature review.
  • Retinoids have been used for the treatment and suppression of cutaneous malignancies in patients with basal cell nevus syndrome, xeroderma pigmentosum, and in patients with recurrent skin cancers as a result of immunosuppression for renal transplantation.
  • We report a 40-year-old male who began to develop multiple squamous cell carcinomas of the skin after treatment with PUVA for severe psoriasis.
  • The numbers of squamous cell carcinomas increased when acitretin was discontinued and decreased when he was taking the drug at a dose of 25 mg daily.
  • Acitretin should be considered as a maintenance therapy for psoriasis patients developing squamous cell carcinomas as a result of PUVA therapy.
  • [MeSH-major] Acitretin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Keratolytic Agents / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Humans. Male. PUVA Therapy / adverse effects. PUVA Therapy / methods. Psoriasis / therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ACITRETIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14578092.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratolytic Agents; LCH760E9T7 / Acitretin
  • [Number-of-references] 22
  •  go-up   go-down


Advertisement
4. Yang QS, Gu JL, Du LQ, Jia LL, Qin LL, Wang Y, Fan FY: ShRNA-mediated Ku80 gene silencing inhibits cell proliferation and sensitizes to gamma-radiation and mitomycin C-induced apoptosis in esophageal squamous cell carcinoma lines. J Radiat Res; 2008 Jul;49(4):399-407
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ShRNA-mediated Ku80 gene silencing inhibits cell proliferation and sensitizes to gamma-radiation and mitomycin C-induced apoptosis in esophageal squamous cell carcinoma lines.
  • To investigate the effects of Ku80 depletion on cell growth and sensitization to gamma-radiation and MMC-induced apoptosis in esophageal squamous cell carcinoma lines.
  • Six human carcinoma cell lines (LNcaP, K562, MDA-MB-231, MCF-7, EC9706, and K150) and normal HEK293 cell line were examined for basal levels of Ku80 protein by western blotting analysis.
  • Cell proliferation was determined with MTT assay and colony formation assay and tumorigenicity in a xenograft model in vitro and in vivo.
  • The cell cycle distribution was determined by Flow cytometry.
  • Ku80 showed higher basal levels in six carcinoma cell lines than in HEK293.
  • Ku80 plays an important role not only in tumorigenesis but also in radiation resistance and chemotherapy resistance in esophageal cancer cells.
  • Hence Ku80 may serve as a promising therapeutic target, particularly for recurrent esophageal tumors.
  • [MeSH-major] Antigens, Nuclear / metabolism. Apoptosis / drug effects. Apoptosis / radiation effects. Carcinoma, Squamous Cell / metabolism. Cell Proliferation / drug effects. Cell Proliferation / radiation effects. DNA-Binding Proteins / metabolism. Esophageal Neoplasms / metabolism. Mitomycin / administration & dosage
  • [MeSH-minor] Cell Line, Tumor. Gamma Rays. Gene Silencing. Humans. RNA, Small Interfering / genetics. Radiation Tolerance / drug effects. Radiation Tolerance / radiation effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403903.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Ku autoantigen; 0 / RNA, Small Interfering; 50SG953SK6 / Mitomycin
  •  go-up   go-down


5. Gayl Schweitzer V: Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck nonmelanomatous skin tumors in elderly patients. Laryngoscope; 2001 Jun;111(6):1091-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck nonmelanomatous skin tumors in elderly patients.
  • OBJECTIVES/HYPOTHESIS: Aggressive nonmelanomatous skin tumors (basal cell carcinoma, squamous cell carcinoma, and Bowen's disease) of the head and neck often occur in Caucasian elderly patients because of prior history of radiation therapy for teenage acne and adenoid hypertrophy; severe solar-induced skin damage, basal cell nevus syndrome, and other genetic skin diseases; chemical carcinogen exposure; and drug-induced immunosuppression.
  • In patients with large, multifocal recurrent tumors, standard therapy with acceptable cosmetic outcomes may be difficult.
  • Photodynamic therapy (PDT) with photosensitizing agents selectively taken up by skin provides a primary or adjunct intraoperative option for treatment of this special group of cancer patients.
  • RESULTS: Twelve cases of aggressive recurrent nonmelanomatous cutaneous tumors of the head and neck were treated.
  • Seven patients were treated with PDT alone for extensive multiple cutaneous lesions or wide-field primary or recurrent nonmelanomatous tumors.
  • CONCLUSIONS: PHOTOFRIN-mediated PDT is an excellent locoregional oncological modality for aggressive primary or recurrent basal cell carcinoma and squamous cell carcinoma, particularly in elderly patients who were previously treated with extensive Mohs microsurgery, surgical resection, and external-beam radiation therapy.
  • Multiple repeat treatments are well tolerated, painless, without systemic morbidity, and amenable to local anesthesia or intravenous sedation for PDT alone, and wound healing and cosmetic outcomes are excellent.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Hematoporphyrin Photoradiation. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Dihematoporphyrin Ether. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11404627.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


6. Lim C, Martin P, Benger R, Kourt G, Ghabrial R: Lacrimal canalicular bypass surgery with the Lester Jones tube. Am J Ophthalmol; 2004 Jan;137(1):101-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The causes of lacrimal obstruction were idiopathic and trauma, congenital agenesis, infection, inflammation, herpes, basal cell carcinoma, radiation therapy, penicillin-induced Steven-Johnsons syndrome, systemic chemotherapy, and facial nerve palsy.
  • Complications were frequent and included extrusion, recurrent extrusion, malposition, obstruction, discomfort, infection, and diplopia.
  • CONCLUSIONS: Conjunctivodacryocystorhinostomy with the insertion of a Jones tube can be expected to improve epiphora significantly in most cases and remains the standard treatment for canalicular obstruction.
  • Complications occur in most cases, requiring replacement, repositioning, and cleaning of the tube by the ophthalmologist over an indefinite period of time.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Intraoperative Complications. Male. Middle Aged. Patient Satisfaction. Postoperative Complications. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14700651.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Soysal HG, Soysal E, Markoç F, Ardiç F: Basal cell carcinoma of the eyelids and periorbital region in a Turkish population. Ophthal Plast Reconstr Surg; 2008 May-Jun;24(3):201-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the eyelids and periorbital region in a Turkish population.
  • PURPOSE: To review the clinical and histopathologic features, treatment, and outcomes of eyelid basal cell carcinomas.
  • METHODS: The clinical records and histopathologic specimens of 311 patients with eyelid basal cell carcinomas were reviewed and analyzed retrospectively.
  • The main outcome measures are patient demographics, clinical characteristics, lesion size, duration of lesion, histologic subtypes, presence of orbital and perineural invasion, severity of peritumorous inflammation, treatment modalities, recurrence rate, tumor-related death, and prognostic features.
  • RESULTS: Two-hundred ninety patients underwent surgery whereas others received radiotherapy or chemotherapy.
  • The most common histologic subtypes were infiltrative, nodular, and basosquamous basal cell carcinomas.
  • Nearly one-third (29.9%) of the patients were previously recurrent.
  • Recurrent basal cell carcinomas were larger, with longer duration of lesion and a higher rate of orbital and perineural invasion.
  • Basosquamous basal cell carcinomas were more likely to have prior recurrences, larger lesion size, and the highest rate of orbital invasion.
  • CONCLUSIONS: In this large case series from a single center, the outcomes were worse than previously reported due to delay in treatment and previous inadequate treatments.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520835.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Huang R, Jaffer S: Imprint cytology of metastatic sialoblastoma. A case report. Acta Cytol; 2003 Nov-Dec;47(6):1123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sialoblastoma is a rare, aggressive and potentially malignant perinatal/congenital tumor that recapitulates the developing salivary gland.
  • CASE: A 75-month-old girl with a history of recurrent sialoblastoma initially diagnosed at 21 months and treated with multiple incomplete surgical excisions, chemotherapy and radiation presented with a solitary lung nodule.
  • The differential diagnoses include neoplasms composed of either basaloid cells and/or admixed hyaline matrix material and included pleomorphic adenoma, basal cell adenoma and adenoid cystic carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / secondary. Lung Neoplasms / secondary. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Glandular and Epithelial / secondary. Parotid Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Diagnosis, Differential. Disease Progression. Epithelial Cells / pathology. Female. Humans. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Parotid Gland / pathology. Parotid Gland / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14674095.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Apalla Z, Sotiriou E, Chovarda E, Lefaki I, Devliotou-Panagiotidou D, Ioannides D: Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol; 2010 Jan;162(1):171-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study.
  • Background Patients with a previous medical history of nonmelanoma skin cancers (NMSCs) often develop multiple or recurrent malignant lesions around the site of the primary tumour.
  • This finding led to the field cancerization theory, which suggests that the entire epithelial surface of the regional skin has an increased risk for the development of malignant lesions.
  • Objectives We sought to investigate whether field-photodynamic therapy (PDT) of extreme photodamaged skin would prevent new NMSCs, in comparison with a control area receiving placebo-PDT, in patients with clinical and histological signs of field cancerization.
  • Methods Forty-five patients, previously diagnosed as having NMSCs of the face or scalp, with actinic keratoses symmetrically distributed over the same regions, were randomized for field treatment with 20% aminolaevulinic acid (ALA)-PDT on one side and placebo-PDT on the other.
  • Results A significant delay in the mean time of appearance and a reduction in the total number of new lesions were observed in the field-PDT protocol, when compared with the control.
  • Conclusions The results obtained showed that field therapy with ALA-PDT confers a significant preventive potential against the formation of new NMSCs in patients with field changes.
  • [MeSH-major] Facial Neoplasms / prevention & control. Head and Neck Neoplasms / drug therapy. Neoplasms, Second Primary / prevention & control. Photochemotherapy. Scalp. Skin Neoplasms / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Keratosis, Actinic / drug therapy. Male. Middle Aged. Photosensitizing Agents / therapeutic use


10. Sebastián Villalón-López J, Arturo Valle-Mejía C, Patiño-Lara A, Moreno-Pérez Bertha A, Alejo Muñoz-López J, Alcantar-Andrade A: Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review. J Cancer Res Ther; 2005 Jul-Sep;1(3):132-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review.
  • Basal cell carcinoma (BCC) is the most frequent type of skin cancer in humans, with cumulative exposure to ultraviolet radiation (UVR) as important risk factor for development of the illness as such as severe solar burns during childhood or adolescence.
  • BCC is mainly located on sun exposed sites, being head and neck the areas of more incidence; although nose, eyelids and periorbitary tissue are unfavorable due to cosmetic results that BCC involves.
  • Several treatment options as surgical and non-surgical are available.
  • The goal of treatment is complete excision of the tumor with preservation of surrounding structures in a way aesthetically acceptable.
  • Mohs' micrographic surgery is the standard treatment for all non-melanoma skin cancer.
  • Orbital exenteration is also used for treatment of malignancies of ocular tissues, mainly squamous cell carcinoma, sebaceous cell carcinoma and BCC.
  • The tissue beneath the surgical site can be left for second-intention granulation or covered with a cutaneous implant of partial thickness.
  • The case of a 77 year-old patient is presented with BCC of inferior eyelid of 14 years duration, formerly managed with radiotherapy and, due to recurrent illness and invasion to the maxillary antrum; he needed supraestructure maxillectomy with left orbital exenteration.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Maxilla / surgery. Orbit Evisceration / methods
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / drug therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998643.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 15
  •  go-up   go-down


11. Lo Muzio L: Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis; 2008;3:32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevoid basal cell carcinoma syndrome (Gorlin syndrome).
  • Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is a hereditary condition characterized by a wide range of developmental abnormalities and a predisposition to neoplasms.
  • The estimated prevalence varies from 1/57,000 to 1/256,000, with a male-to-female ratio of 1:1.
  • Main clinical manifestations include multiple basal cell carcinomas (BCCs), odontogenic keratocysts of the jaws, hyperkeratosis of palms and soles, skeletal abnormalities, intracranial ectopic calcifications, and facial dysmorphism (macrocephaly, cleft lip/palate and severe eye anomalies).
  • Recurrent jaw cysts occur in 90% of patients.
  • Clinical diagnosis relies on specific criteria.
  • Gene mutation analysis confirms the diagnosis.
  • Antenatal diagnosis is feasible by means of ultrasound scans and analysis of DNA extracted from fetal cells (obtained by amniocentesis or chorionic villus sampling).
  • Surgery for BBCs is indicated when the number of lesions is limited; other treatments include laser ablation, photodynamic therapy and topical chemotherapy.
  • [MeSH-major] Basal Cell Nevus Syndrome

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2003 Sep;121(3):478-81 [12925203.001]
  • [Cites] Clin Exp Dermatol. 2003 Nov;28 Suppl 1:19-23 [14616807.001]
  • [Cites] Dermatol Surg. 2003 Dec;29(12):1236-40 [14725671.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):934-41 [14871823.001]
  • [Cites] Arch Pathol Lab Med. 2004 Mar;128(3):313-7 [14987156.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jul;33(5):458-62 [15183409.001]
  • [Cites] J Dermatolog Treat. 2004 Apr;15(2):120-1 [15204165.001]
  • [Cites] Clin Exp Dermatol. 2004 Sep;29(5):542-4 [15347344.001]
  • [Cites] Hum Mutat. 2004 Nov;24(5):441 [15459969.001]
  • [Cites] Arch Fr Pediatr. 1968 Nov;25(9):1083-93 [5728392.001]
  • [Cites] Med Hist. 1969 Jul;13(3):294-7 [4893629.001]
  • [Cites] J Neurosurg. 1971 Nov;35(5):577-84 [5000945.001]
  • [Cites] Birth Defects Orig Artic Ser. 1971 Jun;7(8):140-8 [4950929.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1976 Jan;84(1):107-12 [1251730.001]
  • [Cites] J Neurosurg. 1979 Jan;50(1):100-2 [758369.001]
  • [Cites] Cancer. 1979 Dec;44(6):2294-305 [509397.001]
  • [Cites] Br J Oral Surg. 1979 Nov;17(2):135-46 [298837.001]
  • [Cites] Hautarzt. 1981 Sep;32(9):455-8 [7275582.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):350-3 [7053833.001]
  • [Cites] J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):815-23 [6950957.001]
  • [Cites] Ann Neurol. 1982 Apr;11(4):372-6 [7103417.001]
  • [Cites] Wien Klin Wochenschr. 1982 Sep 3;94(16):430-4 [7147982.001]
  • [Cites] Med Pediatr Oncol. 1983;11(3):178-9 [6855699.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):231-6 [6703200.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Feb;47(2):210-2 [6707662.001]
  • [Cites] Can Med Assoc J. 1985 May 1;132(9):1037-8 [3986729.001]
  • [Cites] N Engl J Med. 1986 Mar 13;314(11):700-6 [3951494.001]
  • [Cites] J Am Acad Dermatol. 1986 Nov;15(5 Pt 1):1023-30 [3537024.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] J Am Acad Dermatol. 1987 May;16(5 Pt 1):964-70 [3584581.001]
  • [Cites] J Comput Assist Tomogr. 1987 Sep-Oct;11(5):901-4 [3655059.001]
  • [Cites] Br J Plast Surg. 1987 Sep;40(5):528-31 [3676586.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):309-14 [9096762.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(5):519-22 [17139991.001]
  • [Cites] Childs Nerv Syst. 2007 Jan;23(1):133-6 [16977487.001]
  • [Cites] Clin Exp Dermatol. 2007 Mar;32(2):202-3 [16780502.001]
  • [Cites] J Neurosurg. 2006 Oct;105(4 Suppl):315-20 [17328283.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Am J Otolaryngol. 2007 Sep-Oct;28(5):360-2 [17826543.001]
  • [Cites] J Drugs Dermatol. 2007 Sep;6(9):910-4 [17941362.001]
  • [Cites] Hum Genet. 2007 Dec;122(5):459-66 [17703323.001]
  • [Cites] Br J Cancer. 1997;76(2):141-5 [9231911.001]
  • [Cites] Ann Plast Surg. 1997 Oct;39(4):366-73 [9339279.001]
  • [Cites] Am J Med Genet. 1997 Dec 19;73(3):304-7 [9415689.001]
  • [Cites] Curr Opin Pediatr. 1997 Dec;9(6):630-5 [9425597.001]
  • [Cites] Hum Genet. 1997 Dec;101(3):317-22 [9439661.001]
  • [Cites] Laryngoscope. 1998 Feb;108(2):280-3 [9473082.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):187-91 [9592846.001]
  • [Cites] J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S82-5 [9703130.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):291-7 [9931336.001]
  • [Cites] Clin Genet. 1999 Jan;55(1):34-40 [10066029.001]
  • [Cites] J Am Dent Assoc. 1999 May;130(5):669-74 [10332131.001]
  • [Cites] Dermatologica. 1963;126:106-23 [13954184.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):495-502 [15545745.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):530-9 [15545751.001]
  • [Cites] Ear Nose Throat J. 2004 Oct;83(10):716-8 [15586876.001]
  • [Cites] Ann Hum Genet. 2004 Nov;68(Pt 6):536-45 [15598212.001]
  • [Cites] Ann Plast Surg. 2004 Dec;53(6):593-5 [15602259.001]
  • [Cites] Arch Dermatol Res. 2005 Jan;296(7):303-8 [15565302.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Dec;44(12):665-8 [15684600.001]
  • [Cites] Am J Med Genet A. 2005 Jan 30;132A(3):324-8 [15690381.001]
  • [Cites] Hum Mutat. 2005 Mar;25(3):322-3 [15712338.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5 Suppl 1):S256-9 [16227103.001]
  • [Cites] Genet Med. 2005 Nov-Dec;7(9):611-9 [16301862.001]
  • [Cites] Prenat Diagn. 2005 Nov;25(11):997-9 [16231297.001]
  • [Cites] J Pathol. 2006 Jan;208(1):17-25 [16294371.001]
  • [Cites] Echocardiography. 2006 Jan;23(1):79-80 [16412193.001]
  • [Cites] Hum Mutat. 2006 Mar;27(3):215-9 [16419085.001]
  • [Cites] Ann Dermatol Venereol. 2006 Feb;133(2):117-23 [16508594.001]
  • [Cites] Tex Heart Inst J. 2006;33(1):88-90 [16572881.001]
  • [Cites] J Med Genet. 2006 Apr;43(4):e16 [16582078.001]
  • [Cites] Tumour Biol. 2006;27(4):175-80 [16675912.001]
  • [Cites] Lasers Surg Med. 2006 Jun;38(5):417-26 [16788928.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6964-71 [16849540.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Aug;20(7):877-8 [16898919.001]
  • [Cites] Br J Cancer. 2006 Aug 21;95(4):548-53 [16909134.001]
  • [Cites] J Dent Res. 2006 Sep;85(9):859-63 [16931872.001]
  • [Cites] Dermatol Ther. 2006 Sep-Oct;19(5):306-14 [17014486.001]
  • [Cites] Dermatol Surg. 2002 Mar;28(3):287-90 [11896785.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):323-31 [12076694.001]
  • [Cites] Am J Med Genet. 2002 Jul 15;110(4):400-3 [12116218.001]
  • [Cites] Mol Genet Metab. 2002 May;76(1):57-61 [12175781.001]
  • [Cites] Hum Mutat. 2002 Sep;20(3):233-4 [12204003.001]
  • [Cites] J Dermatolog Treat. 2002 Sep;13(3):123-7 [12227875.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):569-72 [12459530.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):47-50 [12604725.001]
  • [Cites] Clin Nucl Med. 2002 Dec;27(12):913-4 [12607884.001]
  • [Cites] Hum Mutat. 2003 Apr;21(4):451-2 [12655573.001]
  • [Cites] Am J Obstet Gynecol. 2003 Apr;188(4):1093-5 [12712116.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5 Suppl):S64-6 [12734479.001]
  • [Cites] Pediatr Neurol. 2003 Mar;28(3):231-4 [12770681.001]
  • [Cites] Neuroradiology. 2003 Jun;45(6):390-2 [12756507.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):618-24 [12879481.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Oct;3(10):575-80 [17019435.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1084-6 [17021131.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5 Suppl):S86-9 [17052541.001]
  • [Cites] Am J Med Genet A. 2006 Dec 1;140(23):2625-30 [16906569.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):790-4 [10782799.001]
  • [Cites] Brain Dev. 2000 Jun;22(4):272-4 [10838118.001]
  • [Cites] J Mol Med (Berl). 2000;78(3):140-6 [10868476.001]
  • [Cites] J Dent Res. 2000 Jun;79(6):1418-22 [10890722.001]
  • [Cites] Cutis. 2000 Jul;66(1):35-8 [10916689.001]
  • [Cites] Arch Dermatol Res. 2000 Sep;292(9):475-6 [11000293.001]
  • [Cites] Br Dent J. 2001 Apr 14;190(7):349-50 [11338037.001]
  • [Cites] J Dermatol Sci. 2001 Sep;27(1):21-6 [11457640.001]
  • [Cites] Dermatologica. 1987;175 Suppl 1:138-44 [3480250.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Dec;64(6):727-30 [3480489.001]
  • [Cites] J Oral Pathol. 1988 Jan;17(1):39-42 [3131508.001]
  • [Cites] J Am Dent Assoc. 1988 Jun;116(7):887-9 [3164743.001]
  • [Cites] J Am Acad Dermatol. 1988 Jul;19(1 Pt 2):176-85 [3165982.001]
  • [Cites] Presse Med. 1988 Nov 26;17(42):2247-50 [2974590.001]
  • [Cites] Dentomaxillofac Radiol. 1987;16(2):99-103 [3333752.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Jun;47(6):629-33 [2656943.001]
  • [Cites] J Am Acad Dermatol. 1989 Jul;21(1):144-5 [2745766.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Aug;47(8):870-3 [2664107.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Aug;15(8):868-71 [2754091.001]
  • [Cites] Int Surg. 1991 Jan-Mar;76(1):64-6 [2045256.001]
  • [Cites] Pediatr Radiol. 1991;21(3):234-5 [2047170.001]
  • [Cites] Genet Couns. 1990;1(3-4):273-7 [2098052.001]
  • [Cites] Am J Med Genet. 1991 Aug 1;40(2):206-10 [1910262.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] Br J Neurosurg. 1991;5(6):643-6 [1772613.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1494-8 [1540957.001]
  • [Cites] Genet Couns. 1991;2(3):157-62 [1801852.001]
  • [Cites] Cell. 1992 Apr 3;69(1):111-7 [1348213.001]
  • [Cites] Pediatr Pathol. 1992 Mar-Apr;12(2):255-62 [1570241.001]
  • [Cites] Pediatr Pathol. 1992 May-Jun;12(3):441-7 [1409143.001]
  • [Cites] Cesk Pediatr. 1993 Mar;48(3):129-32 [8495514.001]
  • [Cites] Dermatology. 1993;186(4):311-2 [8513207.001]
  • [Cites] J Med Genet. 1993 Jun;30(6):460-4 [8326488.001]
  • [Cites] Am J Hum Genet. 1993 Sep;53(3):760-7 [8352281.001]
  • [Cites] Hum Mol Genet. 1994 Mar;3(3):447-8 [8012356.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):272-81 [8042672.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):282-90 [8042673.001]
  • [Cites] Lancet. 1994 Aug 13;344(8920):477 [7914587.001]
  • [Cites] Bol Asoc Med P R. 1993 Jan-Mar;85(1-3):24-6 [8060441.001]
  • [Cites] Prenat Diagn. 1994 Aug;14(8):725-7 [7991513.001]
  • [Cites] Genomics. 1994 Aug;22(3):505-11 [8001963.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):472-80 [7856756.001]
  • [Cites] Pediatr Dermatol. 1994 Dec;11(4):323-6 [7899182.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):113-25 [7712637.001]
  • [Cites] Br J Radiol. 1995 Apr;68(808):361-8 [7795971.001]
  • [Cites] Br J Radiol. 1995 Jun;68(810):596-9 [7627481.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):85-7 [8528259.001]
  • [Cites] Arch Dermatol. 1996 Jan;132(1):94-5 [8546496.001]
  • [Cites] Neurology. 1996 Feb;46(2):574-6 [8614540.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Br J Ophthalmol. 1996 Apr;80(4):378 [8703894.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):202-6 [8762878.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):7-8 [8782809.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Histopathology. 1996 Sep;29(3):247-52 [8884353.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):129-34 [8906787.001]
  • [Cites] J Neurosurg. 1997 Feb;86(2):286-8 [9010431.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • (PMID = 19032739.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 164
  • [Other-IDs] NLM/ PMC2607262
  •  go-up   go-down


12. Nashan D, Luger TA: [Cytokines: current status and prospects in the treatment of skin tumors]. Hautarzt; 2001 Aug;52(8):691-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytokines: current status and prospects in the treatment of skin tumors].
  • Various therapeutic options using cytokines have been described in the treatment of melanoma, T cell lymphoma, B cell lymphoma, squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma.
  • The treatment regimens include cytokine substitution, cytokine induction, cytokine transfection and therapeutic cytokine constructs.
  • In the adjuvant treatment of melanomas, IFN-alpha has become well established.
  • IL-2 has a role in the therapy of advanced melanomas as well as in vaccination strategies.
  • Further possible therapeutic immune modulations, which have been evaluated in experimental approaches and pilot studies, include treatment with IL-4, IL-7 and GM-CSF.
  • Treatment with IL-12 promises to open new perspectives.
  • A well established regimen in the treatment of T cell lymphoma stages Ia-IIb is the combination of PUVA and IFN-alpha.
  • IL-2, IFN-gamma, and the fused cytokine-toxin molecules DAB389IL-2 offer further therapeutic alternatives.
  • B cell lymphomas are treated with antibody-IL-2 fusion proteins.
  • Advanced or inoperable squamous cell carcinoma and basal cell carcinoma may be treated with local IFN-alpha injections.
  • IFN-alpha or TNF-alpha may be considered for the treatment of recurrent or advanced Merkel cell carcinoma.
  • In dermatological oncology cytokine treatment focuses on melanome an T cell lymphome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Merkel Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cytokines / therapeutic use. Lymphoma / drug therapy. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Humans. Interferon-alpha / therapeutic use. Interleukins / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Melanoma, Experimental / drug therapy. Mice. Neoplasm Recurrence, Local / drug therapy. PUVA Therapy. Palliative Care. Tumor Necrosis Factor-alpha / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11544938.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Interferon-alpha; 0 / Interleukins; 0 / Tumor Necrosis Factor-alpha; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 96
  •  go-up   go-down






Advertisement